Genomics Reporting Implementation Guide
3.0.0 - STU3 International flag

This page is part of the Genetic Reporting Implementation Guide (v3.0.0: STU3) based on FHIR (HL7® FHIR® Standard) R4. This is the current published version. For a full list of available versions, see the Directory of published versions

Example Procedure: genomicstudy-trio2

Generated Narrative: Procedure genomicstudy-trio2

Genomic Study Analysis Extension: Procedure: extension = GRCh38,->Father Denovo (official) (no stated gender), DoB Unknown ( Medical record number: 6789-11111 (use: temp, )),->Mother Denovo (official) (no stated gender), DoB Unknown ( Medical record number: 0987-11111 (use: temp, )),Parental Sequence Variation Detection Using Next Generation Sequencing,->Procedure Sequencing of entire coding region of gene (procedure),,,,; instantiatesUri = https://pubmed.ncbi.nlm.nih.gov/33927380/; status = completed; category = Laboratory; performed[x] = 2023-10-01

Genomic Study Referrer Extension: Practitioner Jane Doel

identifier: http://www.somesystemabc.net/identifiers/genomicstudies/urn:uuid:1111-1111-1111-1113 (use: temp, )

status: Completed

category: Laboratory

code: Trio Analysis

subject: Child Denovo (official) (no stated gender), DoB Unknown ( Medical record number: 1234-11111 (use: temp, ))

performed: 2023-10-01

asserter: Practitioner Jane Doel

note: De novo mutation study of the patient. The Prenatal Trio Whole Exome Sequencing (Prenatal Trio WES) test is ordered by a physician and must be accompanied with a consent form and detailed clinical information. In general, the test is used when prenatal imaging detects an anomaly that strongly suggests that there is an underlying genetic etiology. Prenatal Trio WES is often considered only after fetal chromosome microarray analysis has been non-diagnostic.